Connect with us
Thursday,20-January-2022

Business

Roche’s antibody Covid drug now available in India

Published

on

antibody-cocktail

Roche India on Monday announced the rollout of its first batch of the antibody cocktail (Casirivimab and Imdevimab) against Coronavirus in India. The cocktail drug will be marketed by Cipla pan-India.

The second batch of the cocktail jabs will be made available by mid-June. Together, they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients, the company said in a statement.

The price for each patient dose [a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750. The maximum retail price for the multi-dose pack (each pack can treat two patients) is Rs 119,500, the statement added.

The Casirivimab-Imdevimab injection is a cocktail of two monoclonal antibodies and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes Covid-19. The monoclonal antibodies are produced by recombinant DNA technology.

The antibody cocktail jab can be administered for the treatment of mild to moderate coronavirus disease in adults and children aged 12 years or older and weighing at least 40 kg, those who are at high risk of developing severe Covid-19 disease, and do not require oxygen, the company said.

The cocktail drug has been shown to help high-risk patients before their condition worsens — reducing the risk of hospitalisation and fatality by 70 per cent and shortening the duration of symptoms by four days.

“Roche is deeply committed to support the ongoing efforts to combat the Covid-19 pandemic, mitigate the deadly second wave and save lives. We are optimistic that the availability of antibody cocktail (Casirivimab and Imdevimab) in India can help in minimising hospitalisation, ease the burden on healthcare systems and play a key role in treatment of high risk patients before their condition worsens,” said V Simpson Emmanuel, Managing Director and CEO, Roche Pharma India, in the statement.

“We are guided by our strong sense of responsibility to address unmet patient needs and look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country,a added Umang Vohra, MD and Global CEO Cipla.

Earlier this month, the Central Drugs Standards Control Organisation (CDSCO) had provided an Emergency Use Authorisation (EUA) for the antibody cocktail (Casirivimab and Imdevimab) in India. It has also received a EUA in the US and several EU countries.

Further, the company said the cocktail drug can be procured only by a medical prescription and may only be administered in settings in which health care providers have immediate access to medications to treat infusion reaction, such as anaphylaxis.

The intravenous administration takes about 20 to 30 minutes. For the subcutaneous route, four syringes of 2.5 ml (2 each of Casirivimab & Imdevimab) need to be administered concurrently at four different sites on the abdomen or thigh.

Patients should be monitored during the infusion and observed for least one hour after the completion of the infusion and 15–30 minutes after the subcutaneous injection

Each pack of antibody cocktail (Casirivimab and Imdevimab) contains one vial of Casirivimab and one vial of Imdevimab totaling 2400 mg of the antibody cocktail (one vial of Casirivimab (1200 mg) and one vial of Imdevimab (1200 mg)).

Each pack can treat two patients as the dosage per patient is a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab) administered by intravenous infusion or subcutaneous route. The vials need to be stored at 2 degrees Celsius to 8 degrees Celsius. If opened for the first patients’ dose, a vial can be used for the second patients’ dose within 48 hours if stored at 2 degrees Celsius to 8 degrees Celsius, the company said.

Business

Toyota launches lifestyle utility vehicle Hilux

Published

on

By

Automaker Toyota Kirloskar Motor (TKM) on Thursday , launched “Hilux” lifestyle utility vehicle.

According to the company, the Ex-showroom prices of the new vehicle will be announced in March 2022 before the start of the deliveries in April 2022.

“Today, as India continues to make larger economic strides, many customers are seeking a sophisticated lifestyle vehicle that delivers exceptional on and off-road prowess and fulfil their daily urban mobility needs be it work or pleasure,” said Masakazu Yoshimura, Managing Director, TKM.

As per the company, the Hilux is loaded with features like a heavy-duty turbo engine and diamond-like carbon coating on the piston rings for maximised frictional efficiency.

“The result is a whopping 500Nm of Torque which is by far the best in the segment,” the company said.

“The Variable Flow Control’ to the power steering has boosted drivability making the steering lighter at low speed in city traffic condition and heavier at higher speeds cruising on a highway.”

Besides, the Hilux comes with an unmatched water wading capacity of 700mm.

It features the same platform (body-on frame chassis construction) that underpins the Innova Crysta and Fortuner.

Globally, the Hilux sales has surpassed 20 million units.

Continue Reading

Business

India’s FY23 GDP to witness ‘meaningful’ growth; to rise by 7.6%: Ind-Ra

Published

on

By

GDP

 India’s FY23 GDP is expected to grow 7.6 per cent year-on-year basis, said India Ratings and Research (Ind-Ra).

As per the ratings agency, after a gap of two years, the Indian economy will show a “meaningful expansion”, as the real GDP in FY23 will be 9.1 per cent higher than the FY20 (pre-Covid) GDP level.

“However, the size of the Indian economy in FY23 will be 10.2 per cent lower than the FY23 GDP trend value,” the agency said.

“A continued weakness in private consumption and investment demand is estimated to contribute 43.4 per cent and 21.0 per cent, respectively, to this shortfall.”

However, it pointed out that if the impact of Omicron on 4QFY22 growth turns out to be greater than the estimate then there could be some upside to the FY23 growth originating from the base effect.

“Nonetheless, there are risks to the ongoing recovery.”

Notably, the agency cited that National Statistical Organisation’s (NSO) advanced estimate (AE) of FY22 showed that private final consumption expenditure (PFCE), grew by only 6.9 per cent YoY in FY22, despite a low base and sales data of many consumer durables showing robust growth.

“This indicates that the consumption demand is still weak and not broad based. In fact, the slowdown in PFCE had begun even before the Covid-19 pandemic had hit the Indian economy.”

“Robust PFCE growth is a must for a sustained growth recovery.”

Besides, it said that wage growth both in the rural and urban areas is facing significant headwinds and has been declining since mid-2020.

“More importantly, real (inflation-adjusted) wages are indicating an erosion of household’s purchasing power. Another factor that has impaired the consumption demand lately is an abrupt rise in the health expenditure of households.”

“These trends may be cyclical in nature, but the picture even at the structural level is not healthy for households.”

Consequently, household savings have declined and their leverage has gone up significantly since FY12, the agency said.

In addition, it estimated that investments, as measured by gross fixed capital formation (GFCF), to grow 8.7 per cent YoY in FY23.

“However, private investments have been down and out over the past several years and Ind-Ra believes the revival of private investment demand will be a slow and drawn-out process.”

“The two developments that can, however, hasten this process are merchandise exports which have shown a surprise turnaround in FY22 and the Production-Linked Incentive Scheme announced by the union government in April 2020.”

Continue Reading

Business

Higher standard deduction for salaried may be part of tinkering

Published

on

By

The Union Budget 2022 may include a higher standard deduction for salaried taxpayers and tax incentives related to affordable housing.

Emkay Global Financial Services said in a report that on the revenue front, gross tax/GDP ratio is expected to increase to 10.7 per cent amid healthy tax buoyancy across segments. Though we do not see any major changes in taxes, we do not rule out minor tinkering in the form of higher standard deduction for salaried taxpayers; tax incentives related to affordable housing; or marginally higher customs duties on PLI-related finished/semi-finished products. Separately, lower non-tax revenue will be led by lower RBI dividends.

The spending focus will likely be on welfare, rural, health and MSMEs. We will also watch for financial sector initiatives (resolutions, higher FPI limits to facilitate divestment in select PSBs on sale, etc.), which could improve the efficacy of the financial sector’s ability to fund the recovery better, the report said.

Amid various push and pull, FY22 GFD/GDP could just about balance at 6.8 per cent. Positive buffers such as bumper RBI surplus, robust tax collection, and higher nominal GDP could get offset by higher payouts than budgeted on food, fertiliser subsidy, health, NREGA, Air India SPV; and possible miss on ambitious divestment targets (despite possible mega LIC IPO in March 2022).

Asset-sale execution will undeniably become the key balancing aspect, especially with a healthy NMP pipeline. We pencil in a modest divestment of Rs 800 billion, and do not account for any major 5G spectrum windfall amid limited clarity on the reserve price, the report said.

The upcoming Budget faces acute policy trade-offs between nurturing a nascent growth recovery and diminishing fiscal space with challenging debt dynamics. The uneven recovery post the pandemic raises questions about the sustainability of demand, especially as the labour market is also potentially divided. For targeted policy responses, fiscal policy tends to be more effective than monetary policy. Thus, a delicate balance needs to be maintained, ensuring the fiscal impulse is maximized to boost potential growth, even as policy adherence to medium-term fiscal sustainability is signalled, the report said.

This would require the expenditure-to-GDP ratio remaining healthy, front-loaded investment-focused stimulus, especially amid its larger multiplier effect on growth and employment. This necessitates innovative reforms, better resource allocation, and possible fiscal funding by aggressive asset sales in the form of existing functional infrastructure monetisation, disinvestments, and strategic sales, among others.

Continue Reading

Trending